CTS Corp

CTS remains in a Stage 4 – Decline with confirmed lower-highs/lower-lows trading beneath declining 9 EMA, 21 EMA, and 50 SMA while oscillators show oversold conditions. Medium-term bias stays bearish, barring bullish participation. Short-term structure lacks clear reversal, suggesting deferred sell execution. Execution should be staged into rallies toward the declining EMAs and 50 SMA resistance zone to align with the dominant downtrend and favor rejection at those levels.

• ↑Revenue rose 11% YoY to $139M, with diversification at 60%
• ↑Medical segment surged 28% YoY to $25M, driven by therapy demand
• ↓Transportation sales fell 7% amid lower global vehicle volumes